Cannabis and Multiple Sclerosis: Spasticity, Pain, and the Sativex Story

Balanced Cannabis Science

25+ Countries

Sativex, a 1:1 THC:CBD mouth spray approved in over 25 countries for MS spasticity, represents the strongest evidence case for a cannabis-based medication outside of epilepsy.

Novotna et al., European Journal of Neurology, 2011

Novotna et al., European Journal of Neurology, 2011

View as image

Multiple sclerosis and cannabis have a relationship that is unique in cannabinoid medicine. While most conditions discussed in the cannabis therapy space have limited clinical evidence, MS spasticity has something approaching a real evidence base. Nabiximols (brand name Sativex), a standardized cannabis extract delivered as an oromucosal spray, has been tested in large, well-designed clinical trials and is approved as a treatment for MS spasticity in more than 25 countries across Europe, the Middle East, and parts of Asia and South America.

Sativex is not approved by the FDA in the United States, a distinction that says more about regulatory strategy than about evidence quality. The evidence supporting its use is substantial enough that it represents, alongside Epidiolex for epilepsy, one of the two strongest cases for a cannabis-derived pharmaceutical.

Understanding the Sativex story, what the clinical trials show, what the drug does and does not do, and how it fits into the broader picture of cannabis and MS, provides a model for what evidence-based cannabinoid therapy looks like.

MS Spasticity: The Problem

Balanced Cannabis Science

Sativex for MS: The Clinical Trial Evidence

Novotna 2011

Design: Enriched enrollment RCT, 572 MS patients

Result: 42% of initial responders achieved ≥30% spasticity improvement

Significance: Established responder identification approach

Flachenecker 2014

Design: Real-world registry, 276 patients

Result: Mean spasticity NRS improved by 25% at 12 weeks

Significance: Confirmed effectiveness outside trial conditions

Kavia 2010

Design: RCT for MS bladder dysfunction

Result: Reduced urgency episodes and incontinence

Significance: Cannabis helps beyond just spasticity

Spasticity Treatment Comparison

BaclofenEffective, inexpensiveSedation, weakness, liver risk

TizanidineLess weakness than baclofenDrowsiness, dry mouth, hepatotoxicity

Sativex (THC:CBD)Multi-symptom relief, tolerableDizziness, not FDA-approved in US

Approved in 25+ countries • Not FDA-approved in US • Not medical adviceSativex for MS Evidence

Spasticity affects approximately 60 to 80 percent of MS patients over the course of their disease. It is caused by damage to the nerve pathways that normally inhibit muscle contraction. When the upper motor neurons in the brain and spinal cord are damaged by MS demyelination, the muscles they control become hyperactive, resulting in stiffness, spasms, and pain.

Spasticity is not just uncomfortable. It interferes with mobility, sleep, bladder function, and sexual function. It contributes to falls. It can cause contractures (permanent shortening of muscles) if not managed. It is one of the most common reasons MS patients cite for disability and reduced quality of life.

Existing treatments for MS spasticity have real limitations. Baclofen, the most commonly prescribed antispasticity drug, causes sedation and weakness. Tizanidine causes drowsiness, dry mouth, and liver toxicity with long-term use. Botulinum toxin injections help focal spasticity but do not address generalized patterns. Intrathecal baclofen pumps are effective but invasive and carry infection risk. Many patients remain inadequately treated despite trying multiple medications.

The Development of Sativex

Sativex was developed by GW Pharmaceuticals (now part of Jazz Pharmaceuticals) in the United Kingdom. It contains a standardized extract of Cannabis sativa with a 1:1 ratio of THC to CBD, delivered as a spray under the tongue or inside the cheek.

The THC:CBD ratio was not arbitrary. During development, GW Pharmaceuticals tested multiple ratios and found that the 1:1 combination provided the best balance of efficacy and tolerability. THC provides the primary antispasticity effect through CB1 receptor activation in the spinal cord, which modulates the stretch reflex and reduces muscle tone. CBD contributes anti-inflammatory effects, may enhance THC's therapeutic effects through pharmacokinetic interaction, and mitigates some of THC's psychoactive side effects.

The oromucosal spray delivery allows relatively rapid absorption (onset within 15 to 45 minutes) with more predictable bioavailability than oral ingestion. Patients self-titrate to their effective dose, typically between 4 and 12 sprays per day, with each spray delivering 2.7 mg THC and 2.5 mg CBD.

The Clinical Trial Evidence

The evidence base for Sativex in MS spasticity includes multiple large, well-designed trials.

Novotna 2011: This was a pivotal enrichment-design trial. In the first phase, 572 MS patients with moderate to severe spasticity that had not responded adequately to existing treatments received open-label Sativex for 4 weeks. Patients who achieved at least a 20 percent improvement in spasticity (the "initial responders," approximately 47 percent) then entered a 12-week randomized, double-blind, placebo-controlled phase.

Among these enriched responders, Sativex produced significantly greater spasticity reduction than placebo. The mean spasticity NRS (Numerical Rating Scale) improvement from baseline was 0.04 points greater in the Sativex group versus placebo in the randomized phase (the difference appears small because both groups had already improved in the open-label phase). More meaningfully, 74 percent of Sativex-treated patients maintained their initial response compared to 51 percent on placebo.

This enrichment design reflects how Sativex is used in clinical practice: patients try it for a trial period, and those who respond continue. Those who do not respond discontinue. This pragmatic approach acknowledges that, like many medications, Sativex does not work for everyone.

Flachenecker 2014: This was a large, prospective, observational study (MOVE 2) involving 276 MS patients starting Sativex in routine clinical practice in Germany. After 3 months, the mean spasticity NRS score improved by 25 percent. After 12 months, the improvement was maintained. This real-world data confirmed that the improvements seen in clinical trials translated to routine practice.

Collin 2010: A randomized, double-blind, placebo-controlled trial of 337 MS patients found that Sativex significantly improved spasticity NRS scores compared to placebo over 15 weeks. The treatment was well tolerated, with the most common side effects being dizziness, fatigue, and nausea.

Wade 2004: An earlier trial found that Sativex improved spasticity, pain, and bladder symptoms in MS patients, suggesting that the benefits extended beyond spasticity alone.

Subjective vs. Objective Improvement

One of the interesting features of the Sativex literature is the discrepancy between subjective and objective measures of spasticity.

Patients consistently report meaningful improvement in their spasticity when using Sativex. The spasticity NRS, a patient-reported score, shows significant improvement across trials. Patients describe reduced stiffness, fewer spasms, better mobility, and improved sleep.

The Modified Ashworth Scale, an objective measure where a clinician rates resistance to passive movement at each joint, often shows smaller or non-significant differences between Sativex and placebo. This has led some critics to question whether the improvement is "real."

This discrepancy is not unique to Sativex. It reflects a genuine limitation of the Ashworth scale, which measures one aspect of spasticity (resistance to passive stretch) but does not capture spasms, spasticity-related pain, or the functional impact on daily activities. Patients experience spasticity as a complex phenomenon that includes stiffness, involuntary movements, pain, and sleep disruption. The Ashworth scale captures only one dimension.

The clinical consensus is that patient-reported improvement matters. If a patient reports significantly less spasticity and better function, and this is sustained over months, the treatment is clinically meaningful regardless of what the Ashworth scale shows. Regulatory agencies in Europe accepted the patient-reported NRS as the primary outcome for Sativex approval.

Pain Management in MS

Pain is one of the most common and undertreated symptoms of MS. It can be neuropathic (from demyelination of sensory pathways), musculoskeletal (from spasticity-related muscle strain), or related to spasms. Conventional pain treatments in MS, including gabapentin, pregabalin, and antidepressants, have modest efficacy and significant side effects.

Cannabis and cannabinoids have moderate evidence for neuropathic pain in general, and MS patients frequently report pain improvement with Sativex and with whole-plant cannabis. The Wade 2004 trial found significant pain improvement alongside spasticity improvement. Multiple patient surveys identify pain as one of the top symptoms improved by cannabis.

For MS patients, the dual benefit of spasticity and pain reduction from a single treatment is particularly attractive, as these symptoms frequently coexist and amplify each other.

Bladder Symptoms

Bladder dysfunction affects approximately 80 percent of MS patients and includes urinary urgency, frequency, incontinence, and nocturia. CB1 receptors are present in the detrusor muscle and in the neural pathways controlling bladder function.

The Wade 2004 trial found that Sativex improved bladder symptoms, and subsequent patient surveys have confirmed that many MS patients report improved bladder control with cannabis use. A small trial by Kavia and colleagues (2010) found that Sativex reduced daily bladder voids and urgency episodes in MS patients, though the study was small and the results require replication.

Sleep Improvement

Sleep disturbance is nearly universal among MS patients and is driven by spasticity, pain, bladder symptoms, and the neurological effects of the disease itself. Cannabis improves sleep through multiple mechanisms: sedation, pain reduction, spasm reduction, and anxiolysis.

In the Sativex trials, sleep improvement was a consistent secondary finding. Given that poor sleep amplifies virtually all other MS symptoms, this benefit has outsized clinical significance.

Why Sativex Is Not FDA-Approved in the US

Despite its approval in more than 25 countries, Sativex has not received FDA approval. This is not because the FDA reviewed the evidence and rejected it. Rather, the path to FDA approval has been complicated by regulatory, commercial, and strategic factors.

FDA approval requires Phase III trials conducted under Investigational New Drug (IND) regulations. GW Pharmaceuticals prioritized FDA approval for Epidiolex (CBD for epilepsy), which received approval in 2018. Sativex requires its own separate regulatory pathway. The Schedule I status of THC in the United States creates additional regulatory hurdles that do not exist in Europe. The commercial calculations for a THC-containing product in a market where whole-plant cannabis is widely available are also complex.

The absence of FDA approval does not reflect a judgment about efficacy. It reflects the reality that drug development is driven by regulatory strategy and commercial viability, not solely by evidence quality.

Whole-Plant Cannabis vs. Sativex for MS

Many MS patients in legal states use whole-plant cannabis rather than Sativex (which is unavailable in the US). The question of whether whole-plant cannabis provides the same benefits is reasonable but largely unanswered.

Sativex provides a standardized, consistent THC:CBD ratio and dose with each spray. Whole-plant cannabis varies in cannabinoid content, terpene profile, and potency. The advantage of Sativex is precision and reproducibility. The potential advantage of whole-plant cannabis is the inclusion of additional cannabinoids and terpenes that may contribute to therapeutic effects through the entourage effect, though this remains debated.

Practical guidance for MS patients using whole-plant cannabis: aim for a roughly balanced THC:CBD ratio (mirroring the Sativex approach), use standardized products where possible (oils, capsules, or tinctures with labeled cannabinoid content), and maintain consistent dosing.

For a broader overview of cannabis in medical contexts, see medical benefits of cannabis.

Practical Guidance for MS Patients

For MS patients considering cannabis or Sativex for spasticity and related symptoms, the following framework applies.

Do not stop disease-modifying therapy. This is critical. Cannabis addresses symptoms. It does not slow the progression of MS. Disease-modifying drugs (interferons, glatiramer acetate, fingolimod, ocrelizumab, and others) reduce relapses and slow disability accumulation. Cannabis cannot replace them.

Start with a balanced THC:CBD approach. The Sativex evidence supports a roughly 1:1 ratio. Whether you are using Sativex (if available) or whole-plant cannabis products, aiming for this balance is reasonable.

Give it a trial period. Following the Sativex trial enrichment model, try cannabis for 4 weeks. If you experience meaningful improvement in spasticity (at least 20 percent by your own assessment), continue. If not, discontinue. Not everyone responds, and continued use without benefit is not warranted.

Monitor for cognitive effects. MS itself causes cognitive impairment in many patients. THC can worsen cognitive symptoms. If you notice worsening memory, concentration, or processing speed, the dose may be too high or THC may not be appropriate for you.

Track multiple symptoms. Record spasticity, pain, sleep quality, bladder symptoms, and mood. Cannabis may help some symptoms more than others, and tracking allows you to identify the most meaningful benefits.

The Bottom Line

Multiple sclerosis spasticity represents the strongest evidence case for cannabis-based therapy after epilepsy. Sativex has been tested in large, well-designed trials and is approved in more than 25 countries. The evidence supports meaningful spasticity reduction, particularly in patients who have not responded to conventional antispasticity medications, along with secondary benefits for pain, sleep, and bladder symptoms.

This does not mean cannabis is a miracle treatment for MS. It helps some patients and not others. It addresses symptoms but does not modify the disease. And the evidence, while stronger than for most cannabinoid therapy indications, still has gaps in long-term safety data and optimal dosing strategies.

But the MS-Sativex story is important beyond MS. It demonstrates what happens when cannabinoid therapy is tested rigorously, with standardized products, controlled trials, and honest reporting of what works and what does not. It is a model for how cannabinoid medicine could develop for other conditions, if the investment in proper clinical trials is made.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before making any changes to your treatment plan.

The Bottom Line

Evidence review of cannabis for MS spasticity covering Sativex development, clinical trials, subjective vs objective measures, pain, bladder, sleep, and FDA status. Sativex: GW Pharmaceuticals 1:1 THC:CBD oromucosal spray; 2.7mg THC + 2.5mg CBD per spray; self-titrated 4-12 sprays/day; onset 15-45 minutes. Novotna 2011: 572 patients enrichment design; 47% initial responders; 74% maintained response on Sativex vs 51% placebo. Flachenecker 2014 MOVE 2: 276 patients real-world Germany; 25% NRS improvement at 3 months, maintained at 12 months. Collin 2010: 337 patients, significant NRS improvement over 15 weeks. Wade 2004: spasticity + pain + bladder improvement. Subjective vs objective: patient NRS consistently significant; Modified Ashworth Scale (clinician-rated) shows smaller/non-significant differences; European regulators accepted patient-reported NRS as primary outcome. Pain: MS neuropathic + musculoskeletal + spasm-related; dual spasticity + pain reduction from single treatment attractive. Bladder: Kavia 2010 — reduced daily voids and urgency. Sleep: consistent secondary benefit across trials. FDA: not rejected — regulatory strategy prioritized Epidiolex; THC Schedule I creates US-specific hurdles; approved 25+ countries. Whole-plant vs Sativex: standardization advantage vs potential entourage benefit; 1:1 ratio practical target for whole-plant users.

Frequently Asked Questions

Does cannabis help MS spasticity?

Yes, with substantial evidence. Nabiximols (Sativex), a 1:1 THC:CBD spray, is approved for MS spasticity in 25+ countries. The Novotna 2011 trial showed approximately 47% of patients achieved meaningful improvement (≥20% reduction). The Flachenecker 2014 real-world study confirmed 25% NRS improvement maintained at 12 months. Multiple other RCTs (Collin 2010, Wade 2004) show consistent benefit. This is the strongest evidence for any cannabis-based medication beyond epilepsy.

Why is Sativex not approved in the United States?

Not because the FDA rejected it — the evidence has not been formally submitted through FDA's regulatory pathway. GW Pharmaceuticals prioritized FDA approval for Epidiolex (CBD for epilepsy) first. Sativex requires separate Phase III trials under IND regulations, and THC's Schedule I status creates additional US-specific regulatory hurdles. The commercial calculations for a THC-containing pharmaceutical in a market with widely available whole-plant cannabis are also complex. The absence of FDA approval reflects regulatory strategy, not evidence quality.

Can I use regular cannabis instead of Sativex for MS?

Many US MS patients do, since Sativex is unavailable. Sativex provides a standardized 1:1 THC:CBD ratio with precise dosing per spray (2.7mg THC + 2.5mg CBD). Whole-plant cannabis varies in content, potency, and consistency. For patients using whole-plant products, aim for a balanced THC:CBD ratio, use standardized products (oils, tinctures with labeled content), and maintain consistent dosing. The clinical trial evidence is for Sativex specifically, not whole-plant cannabis.

Does cannabis replace MS disease-modifying therapy?

No. This is critical. Cannabis addresses symptoms (spasticity, pain, sleep, bladder dysfunction) but does not slow MS progression. Disease-modifying drugs (interferons, glatiramer acetate, fingolimod, ocrelizumab) reduce relapses and slow disability accumulation. Cannabis cannot replace them. Following the Sativex model, try cannabis for 4 weeks — if you experience meaningful improvement, continue as an adjunct. If not, discontinue.

Why do patients report more improvement than clinical scales show?

The Modified Ashworth Scale (clinician-rated) measures only resistance to passive stretch — one dimension of spasticity. Patients experience spasticity as stiffness, involuntary spasms, spasticity-related pain, and sleep disruption. The patient-reported NRS captures this broader experience. European regulators accepted patient-reported NRS as the primary outcome for Sativex approval, acknowledging that if patients consistently report significantly less spasticity and better function over months, the treatment is clinically meaningful.

What MS symptoms besides spasticity does cannabis help?

Multiple symptoms across trials and surveys. Pain (neuropathic, musculoskeletal, spasm-related) improved in the Wade 2004 trial and is consistently ranked among top benefits. Bladder dysfunction (urgency, frequency, nocturia) — Kavia 2010 found reduced daily voids and urgency. Sleep improvement is a consistent secondary finding across Sativex trials, with outsized clinical significance since poor sleep amplifies virtually all other MS symptoms. The dual benefit of addressing multiple symptoms simultaneously is a key advantage.